Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study
Authors:
Open Access
- 9 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (3) , 196-204
Abstract
Aims: Previous studies on the cost-effectiveness of screening for atrial fibrillation (AF) are based on assumptions of long-term clinical effects. The STROKESTOP study, which randomised 27 975 persons aged 75/76 years into a screening invitation group and a control group, has a median follow-up time of 6.9 years. The aim of this study was to estimate the cost-effectiveness of population-based screening for AF using clinical outcomes. Methods and results: The analysis is based on a Markov cohort model. The prevalence of AF, the use of oral anticoagulation, clinical event data, and all-cause mortality were taken from the STROKESTOP study. The cost for clinical events, age-specific utilities, utility decrement due to stroke, and stroke death was taken from the literature. Uncertainty in the model was considered in a probabilistic sensitivity analysis. Per 1000 individuals invited to the screening, there were 77 gained life years and 65 gained quality-adjusted life years. The incremental cost was €1.77 million lower in the screening invitation group. Gained quality-adjusted life years to a lower cost means that the screening strategy was dominant. The result from 10 000 Monte Carlo simulations showed that the AF screening strategy was cost-effective in 99.2% and cost-saving in 92.7% of the simulations. In the base-case scenario, screening of 1000 individuals resulted in 10.6 [95% confidence interval (CI): −22.5 to 1.4] fewer strokes (8.4 ischaemic and 2.2 haemorrhagic strokes), 1.0 (95% CI: −1.9 to 4.1) more cases of systemic embolism, and 2.9 (95% CI: −18.2 to 13.1) fewer bleedings associated with hospitalization. Conclusion: Based on the STROKESTOP study, this analysis shows that a broad AF screening strategy in an elderly population is cost-effective. Efforts should be made to increase screening participation.Keywords
Funding Information
- Swedish Heart and Lung Foundation
- Stockholm County Council
- The Tornspiran Foundation
- King Gustav V and Queen Victoria’s Freemasons’ Foundation
- Klebergska Foundation
- Scientific Council of Halland Region
- Southern Regional Healthcare Committee
- Swedish Stroke Fund
- Carl Bennet AB
- Boehringer Ingelheim
- Bayer, and Bristol-Myers Squibb–Pfizer
This publication has 44 references indexed in Scilit:
- Factors that influence awareness and treatment of atrial fibrillation in older adultsQJM: An International Journal of Medicine, 2013
- Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6Value in Health, 2012
- Mammography Screening and Breast Cancer Mortality in SwedenJNCI: Journal of the National Cancer Institute, 2012
- Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP)EP Europace, 2012
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Atrial Fibrillation and Antithrombotic Therapy in a 75-Year-Old PopulationCardiology, 2007
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- A comparison of individual and social time trade-off values for health states in the general populationHealth Policy, 2006
- Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial FibrillationNew England Journal of Medicine, 2003
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991